ŠPINAROVÁ, Lenka, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Jindřich ŠPINAR, Jiří PAŘENICA, Ondřej LUDKA, Karel LÁBR, F. MALEK, P. OSTADAL, D. VONDRAKOVA, Josef TOMANDL, Jana VEVERKOVÁ, Jolana LIPKOVÁ, Klára BENEŠOVÁ and Jiří JARKOVSKÝ. Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities. Online. Journal of Cardiovascular & Diseases Diagnosis. (Romania): OMICS International, 2018, vol. 6, No 4, p. 1-5. ISSN 2329-9517. Available from: https://dx.doi.org/10.4172/2329-9517.1000326. [citováno 2024-04-24]
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities
Authors ŠPINAROVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution), Monika ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Karel LÁBR (203 Czech Republic), F. MALEK (203 Czech Republic), P. OSTADAL (203 Czech Republic), D. VONDRAKOVA (203 Czech Republic), Josef TOMANDL (203 Czech Republic, belonging to the institution), Jana VEVERKOVÁ (203 Czech Republic, belonging to the institution), Jolana LIPKOVÁ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution) and Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution)
Edition Journal of Cardiovascular & Diseases Diagnosis, (Romania), OMICS International, 2018, 2329-9517.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Romania
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/18:00103531
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.4172/2329-9517.1000326
Keywords in English Chronic heart failure; AHEAD score; Copeptin; Midregional pro-adrenomedullin; Prognosis
Tags EL OK, rivok
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 6/6/2019 09:08.
Abstract
The aim of the study is to evaluate the impact of new humoral substances: copeptin and mid- regional proadrenomedullin (MR-proADM) on one-year survival of patients with stable systolic chronic heart failure (CHF) and to compare them with AHEAD score assessing the comorbidities. The FAR NHL (FARmacology and NeuroHumoraL activation) registry is a database of patients with stable CHF (ejection fraction (EF) <50%) treated in specialized HF departments. AHEAD score is a simple bed-side mortality predictive model based on age and comorbidities. Primary endpoint after 1-year follow-up was: death or hospitalization for decompensation of HF or heart transplantation or LVAD implantation. To whole FAR NHL registry, a total amount of 1088 patients were included, in 552 of them the levels of copeptin and MR-proADM were available. Mean age was 65+12 years, mean EF was 31+9%. Patients without primary endpoint were assigned as group A (469 pts), those with the primary endpoint group B (83 pts). There were statistically significant differences between the groups in the levels of copeptin: group A median 15.9 pmol/l (3.4-50.9) vs group B 23.7 pmol/l(5.0-89.44) (p<0.001), MR-proADM: group A median 0.63 nmol/l(0.32-1.34) vs group B 0.74 nmol/l (0.4-1.94) (p<0.001). Relationship of AHEAD score to primary endpoint in the first year of follow-up was not significant, but within 24th month it reached statistical significance: p= 0.017. Patients with higher AHEAD score (more comorbidities) reached more often the primary end-point.
PrintDisplayed: 24/4/2024 05:44